Hospitals are sitting on a quiet, expensive blind spot: patent expiration intelligence.
Not the kind you hear about in boardrooms—where “biosimilars” and “generic launches” are treated like distant market events. I mean the operational reality: when a …

Generic launches don’t “just happen.” They’re engineered by time, law, and leverage.
If you’re still forecasting generic drug launch dates using spreadsheets and historical averages, you’re already behind. In today’s patent landscape—where exclusivit…

The FDA Orange Book isn’t just a database—it’s a talent map.
Most people treat the Orange Book like a compliance tool: a place to confirm patents, check exclusivity, and move on. But if you’re in business development, licensing, or competitive intellig…

Biotech investors love “pipeline value,” but most portfolios are still ranked like spreadsheets—without a disciplined way to translate timing and risk into profitability.
That’s where NPV and the Profitability Index (PI) stop being academic finance ter…

The “patent cliff” isn’t just a pharma problem—it’s a talent problem.
When blockbuster drugs lose exclusivity, the headlines focus on revenue, pricing pressure, and pipeline triage. But there’s another cliff that rarely gets discussed: the talent cliff…

Overstocking branded drugs isn’t just a balance-sheet problem—it’s a patent-timing problem.
For wholesalers, the risk isn’t theoretical. It shows up as expensive inventory that can’t be sold at the expected margin, write-downs that hit quarterly earnin…

Big Pharma doesn’t just “restructure” when a patent cliff hits. It repositions—and the earliest signal often isn’t in earnings calls. It’s in hiring.
Here’s the hidden hiring signal many investors and operators miss: patent cliff events don’t only chan…

Biosimilars are no longer a “someday” play. They’re a sourcing strategy.
If you’re still treating biosimilar switching as a procurement afterthought, you’re likely paying the price twice: first in missed timing, then in avoidable supply and contracting…

Pharma has a familiar playbook: take an old molecule, repackage it as “new,” and price it like it’s never been seen before.
In a world where patients, payers, and policymakers are increasingly focused on drug affordability, the industry’s justification…

Pharma hiring is broken—at least when it comes to how we find “the best scientists.”
Most recruiters still treat talent like a spreadsheet: search titles, scan keywords, match therapeutic areas, move on. But in life sciences, where innovation is cumula…